Advertisement

U.S. Markets open in 59 mins

S&P Futures
5,875.00
-21.25(-0.36%)
Dow Futures
43,048.00
-129.00(-0.30%)
Nasdaq Futures
20,435.75
-83.75(-0.41%)
Russell 2000 Futures
2,245.70
-9.80(-0.43%)
Crude Oil
71.13
+0.57(+0.81%)
Gold
2,749.00
+10.10(+0.37%)

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

0.9427

+0.1027

(+12.23%)

At close: 04:00PM EDT

0.9302

-0.01

(-1.33%)

Pre-Market:

08:18AM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim results expected November 2024.BCC is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and com
GuruFocus.com
Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Biofrontera Inc (BFRI) reports a 34% revenue increase and significant expense reductions, setting the stage for future profitability.